Total Visits

Views
A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)130

Total Visits Per Month

Μάρτιος 2024Απρίλιος 2024Μάϊος 2024Ιούνιος 2024Ιούλιος 2024Αύγουστος 2024Σεπτέμβριος 2024
A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)2010291

Top country views

Views
Πολωνία62
Ηνωμένες Πολιτείες21
Κύπρος10
Κίνα5
Ιρλανδία3
Γαλλία2
Ελλάδα2
Ινδία2
Αργεντινή1
Αυστραλία1

Top cities views

Views
Warsaw62
Limassol10
San Ramon6
Beijing4
Dublin3
Menlo Park3
San Mateo3
Athens2
Delhi2
Des Moines2